Glossary — Drugs

These are the jargon, acronyms, and constructs a non-expert hits in the Drugs whitepaper. Use this as a reading companion; the filing remains the source of truth.

• Contingency management (CM)
  Incentive-based treatment with the strongest evidence for stimulant use disorder — boxed in by federal fraud-and-abuse rules.
• Methadone / OTP clinics
  ~2,000 federally structured opioid treatment programs; methadone dispensing is clinic-bound by regulation layered on statute.
• Stimulant use disorder
  Meth/cocaine dependence — where CM evidence is strong and legal constraints bind hardest.
• IMD exclusion
  Medicaid's Institutions for Mental Diseases rule that limits payment in certain residential settings (also relevant in mental health).
• SAMHSA
  Federal behavioral-health agency whose rules and grants shape treatment capacity and CM/OTP practice.
• Overdose decline / VSRR
  Vital Statistics Rapid Release and related CDC series showing large recent drops from the 2023 peak — causes still contested.
• Fentanyl supply shock
  Leading candidate explanation for falling deaths; the filing notes 2026 reexamination of that evidence.
• Portugal decriminalization
  Often-cited precedent; the filing root-traces what actually changed versus myth.
• Oregon Measure 110
  State drug-decriminalization experiment; findings and walk-backs are scored as evidence, not slogans.
• Harm reduction
  Interventions that reduce death and disease without requiring abstinence first (naloxone, syringes, etc.).
• RCT / evidence hierarchy
  How the desk ranks treatment claims — randomized trials vs observational vs advocacy arithmetic.
• Fraud-and-abuse / inducement rules
  Federal constraints that treat patient incentives as kickbacks — the legal box around CM.

Scope note: docs/glossary-scope.md. Challenge a definition: [email protected].